Results 161 to 170 of about 1,570 (204)

Patient characteristics, treatment patterns, and survival outcomes in patients with castration-resistant prostate cancer: results from the J-CaP registry. [PDF]

Jpn J Clin Oncol
Onozawa M, Kawai T, Hinotsu S, Saito A, Mitomi T, Uno S, Kume H, Japan Study Group of Prostate Cancer (J-CaP).   +7 more
europepmc   +1 more source

Darstellung von {Delta}-4-Androsten-6,17-dion

, 1941
openaire   +2 more sources

Polymorphic ventricular tachycardia and cardiac arrest from abiraterone-induced hypokalemia: a case report. [PDF]

J Med Case Rep
Mao J, Chang AK, Chin S, Preet K, Torosyan N, Sarkissian S, Ebinger J.   +6 more
europepmc   +1 more source

Low-dose abiraterone plus Olaparib as a late-line treatment for mCRPC patients without BRCA1/2 mutations: a multicenter retrospective pilot study. [PDF]

Sci Rep
Chen S, Zhong D, Yu C, Cai D, Wei Q, Yang M, Li T, Zhu Q, Ye L, Wei Y, Wu J.   +10 more
europepmc   +1 more source

Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors. [PDF]

J Natl Cancer Inst
Faraj KS, Oerline M, Kaufman SR, Dall C, Srivastava A, Caram MEV, Shahinian VB, Hollenbeck BK.   +7 more
europepmc   +1 more source

rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC. [PDF]

Future Oncol
Chi KN, McKay RR, Sandhu S, Arranz JA, Barthélémy P, Hadaschik B, Matsubara N, Shore ND, Ye D, Cascella T, Irincheeva I, Kreiser S, Thiery-Vuillemin A, Rathkopf DE.   +13 more
europepmc   +1 more source

Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: An Analysis of Real-World Practice Patterns from the CancerLinQ Database. [PDF]

Urol Oncol
Eule CJ, Kuna EM, Robin TP, Gershman B, Flaig TW, Kim SP.   +5 more
europepmc   +1 more source

Efficacy and safety of drospirenone as a progestin-only pill in Japanese women: A phase III study. [PDF]

J Obstet Gynaecol Res
Kitamura K, Colli E, Kikuyama R, Kurihara Y, Azuma R, Kagawa T.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

2‐(Hydroxymethyl)androstene Derivatives

Liebigs Annalen der Chemie, 1987
Abstract3‐Hydroxy‐2‐hydroxymethyl‐ (2 and 3) and 3‐hydroxymethyl‐3‐oxoandrostenes 4 were prepared from 2‐hydroxymethylene derivatives 1. The configurations of the chiral centers were determined on the basis of chiroptical, spectroscopical, and X‐ray analytical data. Furthermore, elimination reaction products (5, 6) were identified.
Vincze Irén, Somlai Csaba, Schneider Gyula, Dombi György, Kálmán Alajos   +4 more
openaire   +1 more source

Biological Evaluation of Androstene Derivatives

Archiv der Pharmazie, 2012
AbstractThe effect of several new dihydroepiandrosterone ester derivatives A2–A6 was demonstrated using female cycling mice, which were synchronized for estrus with luteinizing hormone‐releasing hormone (LHRH) and injected with the steroids. The binding to the progesterone receptor (PR), was obtained from the cytosol of uteri from adult estrogen‐primed
Mariana, Garrido, Eugene, Bratoeff, Mario, García-Lorenzana, Yvonne, Heuze, Juan, Soriano, Norma, Valencia, Francisco, Cortes, Marisa, Cabeza   +7 more
openaire   +2 more sources